ARCHIVES

ODAC Rejects Amsacrine NDA, Renews Idarubicin

This article is from The Cancer Letter archive.

Vol. 16 No. 35 | September 14, 1990

Download PDF Visit The Full Archive

Related Articles

ODAC Actions: Large Subset analysis Of CALGB Study Was Basis for BMS Taxol Application

September 24, 1999

No Evidence Of Fraud Found In NCI Audit Of NSABP Trials

April 29, 1994

“We’d Ban Cigarettes’ If Nicotine Were a Drug, FDA Commissioners Says

February 14, 1992

Breast Density Does Not Raise Breast Cancer Death Rates

August 31, 2012

Denman Hammond, NCCF Founder, Receives Award.

November 17, 2000

News Analysis: Filing Will Ignite Complex Litigation Costing Millions, With Uncertain Rewards

March 9, 2012